In recent years, CIDP has received increasing attention due to its high misdiagnosis rate, along with the publication of new ...

with the initial launch of VYVGART Hytrulo in CIDP already transforming treatment expectations. She highlighted that 25% of CIDP prescribers were first-time VYVGART users. Management anticipates ...

In a statement, Argenx said that the subcutaneously administered drug is the first “meaningful” new treatment option for the approximately 24,000 people living with CIDP in the US in more than ...

The "Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Pipeline Insight, 2025" report has been added to ResearchAndMarkets.com's offering.A recent comprehensive analysis of the Chronic ...

Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is a progressive or relapsing neuropathy likely caused by an autoimmune attack on the peripheral nerves. A number of treatment ...

Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today reported ...

Largest safety data set on FcRn blocking demonstrates consistent, favorable safety profileof VYVGART and VYVGART HytrulogMG patients on VYVGART ...

Findings of predominant demyelination on the nerve biopsy can be used in conjunction with the other studies and the clinical presentation to suggest a diagnosis of CIDP. Once the diagnosis is secured, ...

with the initial launch of VYVGART Hytrulo in CIDP already transforming treatment expectations. She highlighted that 25% of CIDP prescribers were first-time VYVGART users. Management anticipates ...